Cargando…
Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form
The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. T...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Österreichische Apotheker-Verlagsgesellschaft
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007604/ https://www.ncbi.nlm.nih.gov/pubmed/21179321 http://dx.doi.org/10.3797/scipharm.1009-11 |
_version_ | 1782194394658504704 |
---|---|
author | Chhalotiya, Usmangani K. Bhatt, Kashyap K. Shah, Dimal A. Baldania, Sunil L. |
author_facet | Chhalotiya, Usmangani K. Bhatt, Kashyap K. Shah, Dimal A. Baldania, Sunil L. |
author_sort | Chhalotiya, Usmangani K. |
collection | PubMed |
description | The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. The drug was found to be stable to dry heat, photodegradation, oxidation and basic condition attempted. Successful separation of the drug from the degradation products formed under acidic stress conditions was achieved on a Hypersil C-18 column (250 mm × 4.6 mm id, 5μm particle size) using acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification was achieved with photodiode array detection at 229 nm over the concentration range 1–25 μg/ml with range of recovery 99.8–101.3 % for DUL by the RP-HPLC method. Statistical analysis proved the method to be repeatable, specific, and accurate for estimation of DUL. It can be used as a stability-indicating method due to its effective separation of the drug from its degradation products, |
format | Text |
id | pubmed-3007604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Österreichische Apotheker-Verlagsgesellschaft |
record_format | MEDLINE/PubMed |
spelling | pubmed-30076042010-12-22 Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form Chhalotiya, Usmangani K. Bhatt, Kashyap K. Shah, Dimal A. Baldania, Sunil L. Sci Pharm Original Papers The objective of the present work was to develop a stability-indicating RP-HPLC method for duloxetine hydrochloride (DUL) in the presence of its degradation products generated from forced decomposition studies. The drug substance was found to be susceptible to stress conditions of acid hydrolysis. The drug was found to be stable to dry heat, photodegradation, oxidation and basic condition attempted. Successful separation of the drug from the degradation products formed under acidic stress conditions was achieved on a Hypersil C-18 column (250 mm × 4.6 mm id, 5μm particle size) using acetonitrile: 0.01 M potassium dihydrogen phosphate buffer (pH 5.4 adjusted with orthophosphoric acid) (50:50, v/v) as the mobile phase at a flow rate of 1.0 ml/min. Quantification was achieved with photodiode array detection at 229 nm over the concentration range 1–25 μg/ml with range of recovery 99.8–101.3 % for DUL by the RP-HPLC method. Statistical analysis proved the method to be repeatable, specific, and accurate for estimation of DUL. It can be used as a stability-indicating method due to its effective separation of the drug from its degradation products, Österreichische Apotheker-Verlagsgesellschaft 2010 2010-10-25 /pmc/articles/PMC3007604/ /pubmed/21179321 http://dx.doi.org/10.3797/scipharm.1009-11 Text en © Chhalotiya et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Papers Chhalotiya, Usmangani K. Bhatt, Kashyap K. Shah, Dimal A. Baldania, Sunil L. Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title | Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title_full | Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title_fullStr | Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title_full_unstemmed | Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title_short | Development and Validation of a Stability-Indicating RP-HPLC Method for Duloxetine Hydrochloride in its Bulk and Tablet Dosage Form |
title_sort | development and validation of a stability-indicating rp-hplc method for duloxetine hydrochloride in its bulk and tablet dosage form |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007604/ https://www.ncbi.nlm.nih.gov/pubmed/21179321 http://dx.doi.org/10.3797/scipharm.1009-11 |
work_keys_str_mv | AT chhalotiyausmanganik developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform AT bhattkashyapk developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform AT shahdimala developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform AT baldaniasunill developmentandvalidationofastabilityindicatingrphplcmethodforduloxetinehydrochlorideinitsbulkandtabletdosageform |